These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 17045785

  • 21. [In vitro activity of fosfomycin against ESBL-producing enterobacteria of urinary origin].
    Hernández MS, García JA, Muñoz JL.
    Rev Esp Quimioter; 2009 Mar; 22(1):25-9. PubMed ID: 19308743
    [Abstract] [Full Text] [Related]

  • 22. Escherichia coli producing SHV-type extended-spectrum beta-lactamase is a significant cause of community-acquired infection.
    Rodríguez-Baño J, Alcalá J, Cisneros JM, Grill F, Oliver A, Horcajada JP, Tórtola T, Mirelis B, Navarro G, Cuenca M, Esteve M, Peña C, Llanos AC, Cantón R, Pascual A.
    J Antimicrob Chemother; 2009 Apr; 63(4):781-4. PubMed ID: 19223299
    [Abstract] [Full Text] [Related]

  • 23. High presence of extended-spectrum beta-lactamases and resistance to quinolones in clinical isolates of Escherichia coli.
    Sorlózano A, Gutiérrez J, de Dios Luna J, Oteo J, Liébana J, Soto MJ, Piédrola G.
    Microbiol Res; 2007 Apr; 162(4):347-54. PubMed ID: 16564161
    [Abstract] [Full Text] [Related]

  • 24. In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002.
    Bouchillon SK, Hoban DJ, Johnson BM, Stevens TM, Dowzicky MJ, Wu DH, Bradford PA.
    Diagn Microbiol Infect Dis; 2005 Apr; 51(4):291-5. PubMed ID: 15808321
    [Abstract] [Full Text] [Related]

  • 25. Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria.
    Sevillano D, Aguilar L, Alou L, Giménez MJ, González N, Torrico M, Cafini F, Garcia-Rey C, Garcia-Escribano N, Prieto J.
    Int J Antimicrob Agents; 2010 Aug; 36(2):137-44. PubMed ID: 20462741
    [Abstract] [Full Text] [Related]

  • 26. [Investigation of the frequency of extended spectrum beta-lactamases and antibiotic resistance in clinical isolates of Escherichia coli and Klebsiella sp].
    Ekşi F, Ozer G, Balci I.
    Mikrobiyol Bul; 2007 Jul; 41(3):447-52. PubMed ID: 17933257
    [Abstract] [Full Text] [Related]

  • 27. Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST).
    Bouchillon SK, Iredell JR, Barkham T, Lee K, Dowzicky MJ.
    Int J Antimicrob Agents; 2009 Feb; 33(2):130-6. PubMed ID: 18995992
    [Abstract] [Full Text] [Related]

  • 28. Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide (2011).
    Sader HS, Flamm RK, Jones RN.
    Diagn Microbiol Infect Dis; 2013 Jun; 76(2):217-21. PubMed ID: 23522845
    [Abstract] [Full Text] [Related]

  • 29. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
    Mushtaq S, Warner M, Ge Y, Kaniga K, Livermore DM.
    J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
    [Abstract] [Full Text] [Related]

  • 30. Comparative in vitro activity of tigecycline against enterobacteria producing two or more extended-spectrum beta-lactamases.
    Vázquez MF, Romero ED, García MI, Rodríguez JA, Bellido JL.
    Int J Antimicrob Agents; 2008 Dec; 32(6):541-3. PubMed ID: 18789848
    [No Abstract] [Full Text] [Related]

  • 31. Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of Gram-positive cocci.
    Tsao SM, Lin HC, Lee CM, Hsu GJ, Chen CM, Sun W, Liu YC, Jang TN, Cheng YJ, Lu PL, Chiang PC, Wang LS, Kung HC, Chuang YC, Shi ZY, Liu JW, Huang CH, Lu CT, Liao CH, Hsueh PR.
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S184-7. PubMed ID: 19013352
    [Abstract] [Full Text] [Related]

  • 32. Agreement assessment of tigecycline susceptibilities determined by the disk diffusion and broth microdilution methods among commonly encountered resistant bacterial isolates: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2008 to 2010.
    Liu JW, Ko WC, Huang CH, Liao CH, Lu CT, Chuang YC, Tsao SM, Chen YS, Liu YC, Chen WY, Jang TN, Lin HC, Chen CM, Shi ZY, Pan SC, Yang JL, Kung HC, Liu CE, Cheng YJ, Chen YH, Lu PL, Sun W, Wang LS, Yu KW, Chiang PC, Lee MH, Lee CM, Hsu GJ, Hsueh PR.
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1414-7. PubMed ID: 22155819
    [Abstract] [Full Text] [Related]

  • 33. High percentage of resistance to ciprofloxacin and qnrB19 gene identified in urinary isolates of extended-spectrum beta-lactamase-producing Escherichia coli in Madrid, Spain.
    Ríos E, Rodríguez-Avial I, Rodríguez-Avial C, Hernandez E, Picazo JJ.
    Diagn Microbiol Infect Dis; 2010 Aug; 67(4):380-3. PubMed ID: 20638608
    [Abstract] [Full Text] [Related]

  • 34. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
    Huang YT, Liao CH, Teng LJ, Hsueh PR.
    Clin Microbiol Infect; 2008 Feb; 14(2):124-9. PubMed ID: 18076671
    [Abstract] [Full Text] [Related]

  • 35. Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus.
    Rose WE, Poppens PT.
    J Antimicrob Chemother; 2009 Mar; 63(3):485-8. PubMed ID: 19109338
    [Abstract] [Full Text] [Related]

  • 36. Molecular epidemiology of Escherichia coli producing extended-spectrum {beta}-lactamases in Lugo (Spain): dissemination of clone O25b:H4-ST131 producing CTX-M-15.
    Blanco M, Alonso MP, Nicolas-Chanoine MH, Dahbi G, Mora A, Blanco JE, López C, Cortés P, Llagostera M, Leflon-Guibout V, Puentes B, Mamani R, Herrera A, Coira MA, García-Garrote F, Pita JM, Blanco J.
    J Antimicrob Chemother; 2009 Jun; 63(6):1135-41. PubMed ID: 19351692
    [Abstract] [Full Text] [Related]

  • 37. A comparison of the activity of tigecycline against multiresistant clinical isolates of Staphylococcus aureus and Streptococcus agalactiae.
    Sorlozano A, Gutierrez J, Roman E, de Dios Luna J, Roman J, Liebana J, Piedrola G.
    Diagn Microbiol Infect Dis; 2007 Aug; 58(4):487-9. PubMed ID: 17509803
    [Abstract] [Full Text] [Related]

  • 38. beta-Lactam resistance phenotype determination in Escherichia coli isolates from University Malaya Medical Centre.
    Wong JS, Mohd Azri ZA, Subramaniam G, Ho SE, Palasubramaniam S, Navaratnam P.
    Malays J Pathol; 2003 Dec; 25(2):113-9. PubMed ID: 16196367
    [Abstract] [Full Text] [Related]

  • 39. Antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) in Spain, 2004-2014.
    Marco F, Dowzicky MJ.
    J Glob Antimicrob Resist; 2016 Sep; 6():50-56. PubMed ID: 27530839
    [Abstract] [Full Text] [Related]

  • 40. A longitudinal analysis of antimicrobial susceptibility in clinical institutions in Germany as part of the Tigecycline Evaluation and Surveillance Trial (2004-2007).
    Seifert H, Dowzicky MJ.
    Chemotherapy; 2009 Sep; 55(4):241-52. PubMed ID: 19468222
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.